Select Page


Below is a sample of existing clinical evidence:

“A single treatment of hUCB-MSCs (human Umbilcial Cord Blood Mesenchymal Stem Cells) resulted in dose-dependent improvements in AD (Atopic Dermatitis) manifestation. Fifty-five percent of patients in high dose hUCB-MSC-treated group showed a 50% reduction in the EASI (Eczema Area and Severity Index) score… the administration of high dose hUCB-MSCs reduced the pruritus score by 58%.”

– “Clinical Trial of Human Umbilical Cord Blood-Derived Stem Cells for the Treatment of Moderate-to-Severe Atopic Dermatitis: Phase I/IIa Studies,” Kim et al, Stem Cells, 2017

Pin It on Pinterest

Share This